FTC Seeks Input On How PBM Rebating Practices Affect Drug ‘Affordability,’ Access

With formal study still stalled, the information collection will enable FTC to examine a ‘wide array’ of pharmacy benefit manager business practices impacting patients, payers and pharmacies.

Last In-Depth FTC Study On PBMs Was 2005 • Source: Alamy

The Federal Trade Commission is requesting public comment on a wide range of pharmacy benefit manager business activities including contract terms, rebates, fees, pricing policies, steering methods, conflicts of interest, and consolidation and how those practices impact patients, physicians, employers, and independent and chain pharmacies.

The request for information “will enable agency staff to study a wide array of PBM business practices and issues and will help inform the agency’s policy and enforcement work,” explains a

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Market Access

More from Pink Sheet